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Summary
The STIKO recommends vaccination with 
the adjuvanted herpes zoster subunit (HZ/
su) inactivated vaccine for the preven­
tion of herpes zoster (HZ) and posther­
petic neuralgia (PHN) for all people age 
60 years and over (standard vaccination).
This recommendation takes into ac­
count the good efficacy of the vaccine, the 
anticipated period of protection it pro­
vides, and the increased risk of severe HZ 
disease and post­zoster pain in individuals 
age 60 years and over. Models of the epide­
miological effects of vaccination show that 
administering the HZ/su vaccine at age 60 
years has the greatest effect in preventing 
all HZ cases, and administering the vac­
cine at age 70 years showed the greatest 
effect in preventing PHN, in a vaccinat­
ed cohort. According to the results of a 
health economics model, the lowest cost 
per quality­adjusted life year (QALY) 
would be achieved with vaccination at age 
65 years. The number of people who need 
to be vaccinated (number needed to vac­
cinate, NNV) to prevent one case of HZ is 
the same for both vaccination ages (60 and 
65 years). In light of the fact that prevent­
ing HZ is the key prerequisite to prevent­
ing complications and late sequelae such 
as PHN, 60 years of age is considered the 
most favorable age for vaccination, to pre­
vent both HZ and its complications.
The STIKO also recommends vaccina­
tion against HZ and PHN with the HZ/
su inactivated vaccine for all people from 
the age of 50 years who have an elevated 
risk of HZ and PHN owing to increased 
health risks as a consequence of an under­
lying disease or immunosuppression (in­
dication­based vaccination). This group 
includes e. g. people with congenital or 
acquired immunodeficiency or immu­
nosuppression, HIV infection, rheuma­
toid arthritis, systemic lupus erythemato­
sus, chronic inflammatory bowel disease, 
chronic obstructive pulmonary disease 
(COPD) or bronchial asthma, chronic re­
nal disease, diabetes mellitus.
The efficacy and safety of the vaccine for 
patients with impaired immune systems 
have been demonstrated in numerous stud­
ies. Stratified data analyses on the efficacy 
of the vaccine have shown no difference in 
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comparison to overall efficacy for patients 
with an underlying disease, e. g., rheuma­
toid arthritis, chronic renal disease, COPD, 
or diabetes mellitus, who were enrolled in 
vaccine marketing authorization studies.
1 Introduction
Herpes zoster (HZ) and its most fre­
quent complication, postherpetic neu­
ralgia (PHN), place a large disease bur­
den and limitations on the life quality of 
people affected in Germany. In March 
2018, the European regulatory authori­
ty approved an adjuvanted HZ subunit 
(HZ/su) vaccine for the prevention of HZ 
and PHN from the age of 50 years (Shin­
grix®; Glaxo SmithKline (GSK), Rixen­
sart, Belgium); this vaccine contains the 
adjuvant AS01B and recombinant varicel­
la zoster virus (VZV) glycoprotein E (gE). 
This background paper summarizes the 
data basis used by the STIKO in its deci­
sion regarding standard vaccination and 
indication­based vaccination with the ad­
juvanted HZ/su inactivated vaccine. The 
present information is also based on the 
data already used in the STIKO decision 
on the live HZ vaccine in its 2017/2018 
recommendations [1]. For example, the 
current disease burden of HZ in Germany 
had already been determined according to 
the STIKO standard operating procedure 
(SOP) [2]. This was followed by systemat­
ic reviews on the efficacy and safety of the 
HZ/su inactivated vaccine and evaluations 
of the data on the vaccine induced peri­
od of protection. A mathematical mod­
el of the potential epidemiological effects 
of HZ vaccination in Germany was con­
ducted, which served as the basis for a 
health economics evaluation of potential 
vaccination strategies. This background 
paper includes a comprehensive appen­
dix as electronic supplementary materi­
al containing further information on the 
systematic reviews conducted as well as 
on the decision process by the STIKO , 
which is available for download at https://
link.springer.com/journal/volumesAn­
dIssues/103.
2 Causes and symptoms
Detailed information on the etiology, 
symptoms, localization, complications, 
and risk factors of HZ was recently pub­
lished in a STIKO background paper pre­
senting the rationale of the STIKO deci­
sion against recommendation of the live 
HZ vaccine as a standard vaccination [1, 
3]. For that reason a detailed description 
is not presented here.
3 Epidemiology
Data on the epidemiology of HZ were also 
published in the aforementioned back­
ground paper [1, 3]. These will be sum­
marized again here, and complemented 
with data on the epidemiology of PHN 
and other complications of HZ, as well as 
a description of the risk factors of HZ and 
PHN.
In Germany, it is estimated that more 
than 300,000 people develop HZ each 
year, and that number is increasing. The 
risk of developing HZ is age dependent. 
From age 10 to 44 years, the incidence of 
HZ is 4/1000 person­years (PY) [4]; from 
age 50 years, the incidence rises steadi­
ly from around 6/1000 PY to more than 
13/1000 PY from age 70 years [4, 5]. The 
incidence of HZ is higher among wom­
en than among men in every age group 
(. Fig. 1).
Hospitalizations owing to HZ and its 
complications also increase with age. The 
reported incidence of HZ cases treated 
in the hospital is 0.13/1000 PY in the age 
group 50–54 years, and rises to around 
1/1000 PY from the age of 80 years [5]. Ac­
cording to hospital diagnosis statistics, the 
annual number of HZ cases among people 
age >50 years treated in hospitals has ap­
proximately doubled in the past 10 years, 
with nearly 20,000 cases in 2015. Compli­
cations are recorded for more than 60% 
of patients hospitalized with HZ, the most 
frequent being HZ with clinical symptoms 
affecting the nervous system and herpes 
zoster ophthalmicus. The percentage of 
hospitalized patients with complications 
remains constant with increasing age in 
people age 50 years and older, but the 
number of patients treated in the hospital 




suchstring=g%FCrtelrose). An analysis of 
data from insured individuals also showed 
an increase with age for all other HZ com­
plications and multiple complications, ex­
cept for HZ meningitis [4].
The risk of PHN following HZ rises 
steadily with age. In the aforementioned 
analysis of data from insured individuals, 
the percentage of PHN cases among all 
HZ cases in the age group 50–54 years was 
approximately 12%, and this increased to 
>20% with age until 80–84 years [4]. In a 
more conservative estimate based on out­
Fig. 1 9 Incidence of 
herpes zoster (HZ) by age 
and sex and proportion 
of postherpetic neuralgia 
(PHN) among HZ cases in 
Germany [5, 43]
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patient diagnosis invoicing, the percent­
age of PHN among people age 50–59 years 
was 3%, and around 8% in those age 70 
years or more [5].
Immunosuppression and other under­
lying diseases have been described as ad­
ditional risk factors for HZ and its compli­
cations. In an analysis of clinical data from 
Germany, the percentage of patients who 
developed PHN in all age groups was 36% 
higher among those with immunosuppres­
sion than among patients with a healthy 
immune system; in those age 50 years and 
over, this rate was 18% higher [4]. Patients 
with immunosuppression were defined in 
this study as those with HIV infection, ma­
lignant tumors, organ or stem­cell trans­
plant recipients, and patients with other 
reasons for immunosuppression.
In a systematic review covering  84 
mostly retrospective cohort studies con­
ducted mainly in North America, Europe, 
and Asia from January 2003 to February 
2017, the following comorbidities were 
identified as risk factors for HZ (RR, rel­
ative risk) [6]:
 5 Rheumatoid arthritis: RR 1.19–2.40
 5 Systemic lupus erythematosus: 
RR 1.29–4.11
 5 Inflammatory bowel disease: 
RR 1.26–1.50
 5 Chronic renal disease: RR 1.14–1.60
 5 COPD: RR 1.17–1.68
 5 Asthma: RR 1.11–1.70
 5 Diabetes mellitus: RR 1.02–1.68
In another systematic review, the risk of 
HZ was examined in patients with rheu­
matoid arthritis, psoriasis, SLE, or chron­
ic inflammatory bowel diseases, as well 
as those who had received immunosup­
pressive therapy with biologics or with 
so­called non­biologic disease modifying 
anti­rheumatic drugs (nbDMARDS) [7]. 
During the time frame 1946–2016, a total 
of 40 randomized controlled trials (RCTs) 
including 20,136 patients and 19 observa­
tional studies with a total of 810,939 pa­
tients were identified. In the meta­analy­
ses of both RCTs (odds ratio (OR) = 1.71, 
95% confidence interval (CI) 1.11–2.64) 
and observational studies (OR = 1.58, 95% 
CI 1.39–1.81), an increased risk of HZ was 
found among patients who received bio­
logics therapy, especially among those 
who had been treated with non­TNF­α 
antagonists (OR = 2.19, 95% CI 1.20–
4.02). In contrast, patients who were treat­
ed with TNF­α antagonists did not have 
a significantly higher HZ risk. Patients 
who received high­dosage nbDMARDS 
or high­dose corticosteroids also showed 
an increased risk.
One study from the United Kingdom 
(UK) analyzed the risk of PHN using data 
from a routine database of patients with 
HZ in primary care [6]. The study find­
ings showed that the incidence of PHN 
was markedly higher in the following risk 
groups: patients with leukemia (14.4%), 
lymphoma (12.1%), myeloma (17%), 
rheumatoid arthritis (9.1%), SLE (9.4%), 
COPD (13.2%), and chronic renal disease 
(10.6%), and patients who received high­
dose corticosteroid therapy (14.5%) and 
homologous stem­cell therapy (29.4%).
Patients with immunosuppression and 
other severe underlying diseases (particu­
larly autoimmune diseases) are at higher 
risk of developing HZ than those with 
healthy immune systems at any age. These 
individuals also more frequently experi­
ence severe progression or complications 
of HZ. For this reason, evidence on the ef­
ficacy and safety of vaccination with the 
HZ/su inactivated vaccine was systemat­
ically reviewed for these populations (see 
Sect. 11.6).
4 Herpes zoster subunit 
inactivated vaccine
An adjuvanted HZ/su inactivated vac­
cine (Shingrix®, manufactured by GSK, 
Belgium) was approved for use in Eu­
rope on 21 March 2018 by the Europe­
an Medicines Agency [7]; the vaccine be­
came available in Germany in May 2018. 
This immunogenic vaccine contains re­
combinant surface glycoprotein E (50 µg) 
of VZV. The HZ/su inactivated vaccine 
also contains the adjuvants AS01B, con­
sisting of monophosphoryl lipid A (MPL) 
from Salmonella minnesota and Quillaja 
saponaria Molina fraction 21 (QS­21), a 
surface­active substance from the South 
American soap bark tree.
The adjuvant contains elements that 
enhance the CD4+ T cell and humoral im­
mune response [8]. Thus, the vaccine can 
trigger a strong, cell­mediated immune re­
sponse in individuals whose adaptive im­
mune system is impaired, e. g., owing to 
immunosenescence or for other reasons 
of immunosuppression. The same adju­
vant was used for the first time in a malar­
ia candidate vaccine for children. There is 
no experience in using this adjuvant out­
side of clinical trials.
One dose (0.5 mL) of the reconstitut­
ed HZ/su inactivated vaccine (powder and 
solvent for producing a suspension for in­
jection) contains 50 µg VZV gE antigen, 
50 µg MPL, and 50 µg QS­21. Additional 
ingredients in the vaccine are as follows. 
The powder (gE antigen) contains sac­
charose, polysorbate 80, sodium dihydro­
gen phosphate dihydrate, and dipotassium 
phosphate; the suspension (AS01B adju­
vant system) contains dioleoylphosphati­
dylcholine, cholesterol, sodium chloride, 
disodium phosphate (anhydrous), potas­
sium dihydrogenphosphate, and water 
for injection purposes. The vaccine does 
not contain any thimerosal or other pre­
servatives. The HZ/su inactivated vaccine 
is approved for the prevention of HZ and 
HZ­attributable PHN in adults 50 years of 
age and older. The vaccination series con­
sists of two vaccinations administered i. m. 
at least 2 months apart. The time frame 
for administration of the second dose can 
be extended up to 6 months after the first 
vaccine dose. The need for and optimal 
time frame of vaccination boosters after 
basic immunization is completed is not 
yet known. The safety and efficacy of the 
vaccine in children and adolescents is not 
yet known. Data are available on simulta­
neous administration with other vaccines, 
addressed in Sect. 10.2. Vaccination is con­
traindicated in cases of hypersensitivity to 
any of the ingredients in the vaccine. No 
data are available on the administration of 
the HZ/su inactivated vaccine to pregnant 
women. In several studies with patients 
receiving immunosuppressive therapy or 
patients with immunodeficiency disease, 
the vaccine has been demonstrated to be 
immunogenic and well tolerated [9].
5 Vaccination aims
The primary aims of vaccination with the 
adjuvanted HZ/su subunit vaccine are 
a reduction in the frequency of HZ and 
prevention of complications and HZ se­
quelae, such as PHN, in adults age 60 
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years and over. The longest possible pro­
tection for vaccinated individuals should 
be achieved.
The aim of indication­based vaccina­
tion is a reduction in the frequency of HZ 
and prevention of complications and HZ 
sequelae in populations with an elevated 
risk of HZ, according to the approved age 
at vaccination of 50 years or over.
6 Method of searching and 
assessing the quality of evidence
The evidence on efficacy and safety of 
the HZ/su inactivated vaccine was re­
viewed and assessed for quality accord­
ing to the STIKO SOP for the systematic 
development of vaccination recommen­
dations [2]. After the STIKO formulat­
ed the primary aims of HZ vaccination, 
and following the methods of the Grad­
ing of Recommendations Assessment, 
Development and Evaluation (GRADE) 
working group, patient­relevant end­
points of HZ vaccination were defined. 
The endpoints HZ, PHN, other compli­
cations (including death), and hospital­
ization were selected for vaccine effica­
cy. The endpoints for vaccine safety were 
non­severe local reactions, severe lo­
cal reactions, non­severe systemic reac­
tions, and severe systemic reactions. All 
endpoints were assessed on a scale of 1–9 
as essential/critical (7–9 points), impor­
tant (4–6 points), or of limited signifi­
cance (1–3 points) in the decision on a 
vaccination recommendation by working 
group members (. Table 1).
To identify clinical studies on vac­
cine safety and efficacy, systematic litera­
ture research following the requirements 
set forth in the PRISMA statement (Pre­
ferred Reporting Items for Systematic Re­
views and Meta­Analyses) was conducted 
using the following databases and taking 
patient­relevant endpoints into account: 
MEDLINE; EMBASE, BIOSIS Previews, 
SciSearch, Cochrane Central Register of 
Controlled Trials, Cochrane Database 
of Systematic Reviews, GLOBAL Health 
[10]. The complete search strategies, flow­
charts, and inclusion and exclusion cri­
teria are provided in the appendix (last 
search date: 4 November 2017). Addition­
ally, reference lists of the studies included 
and the reviews identified were screened 
for other potentially relevant studies. No 
limitations were placed on publication sta­
tus or language.
The literature research and data extrac­
tion were conducted by two independent 
investigators (AS, JK). The relevant study 
characteristics of the original studies that 
fulfilled the inclusion criteria were record­
ed using a standardized extraction form 
and their internal and external validity was 
evaluated. Discrepancies between the two 
investigators were discussed until consen­
sus was reached. The Cochrane risk of bias 
tool was used to assess the risk of bias in 
randomized controlled trials (RCTs) [11].
We entered the extracted data on pa­
tient­relevant endpoints from the included 
studies into RevMan (version 5.2) review 
management software, and RRs and cor­
responding 95% CIs of the vaccine group 
compared with the placebo group were cal­
culated for the respective endpoints. If more 
than one study was available, a meta­analy­
sis was conducted and the pooled estimates 
determined. If heterogeneity was pres­
ent (assessed using the I2 statistic), a ran­
dom­effects model was used; otherwise, the 
data were summarized using a fixed­effects 
model. Using the pooled RR, the formula 
((1 – RR) · 100) was applied to calculate the 
vaccine efficacy or effectiveness or the risk 
of adverse side effects of vaccination.
To compile the GRADE evidence pro­
file, pooled data from the endpoints de­
fined as “critical” and “important” were 
entered into the GRADE profiler (version 
3.6), and the quality of evidence in all in­
cluded studies were assessed for each end­
point, according to the following aspects: 
study design, heterogeneity and precision, 
indirect evidence, effect size, and publica­
tion bias. Assessment of the overall qual­
ity of evidence across all endpoints was 
conducted using the lowest quality of evi­
dence in those endpoints defined as “crit­
ical” [12, 13].
Table 1 Hierarchy of patient-relevant endpoints for the evaluation of efficacy and safety of the herpes zoster subunit inactivated vaccine
Type of 
endpoint




Efficacy Adults ≥ 50 yearsb Vaccination with 
HZ/su inactivated 
vaccine 
No vaccination; Placebo vaccination; 
Other vaccination








Safety Adults ≥ 50 yearsb Vaccination with 
HZ/su inactivated 
vaccine 
No vaccination; Placebo vaccination; 
Other vaccination
Local reactions, not severe 3
Severe local reactions 7
Systemic reactions, not 
severe
5
Severe systemic reactions 8
aScale from 1–9: essential/critical (7–9 points), important (4–6 points), or of limited significance (1–3 points). Each endpoint must be assessed on its own. The same score 
can be assigned to multiple endpoints, as different endpoints can be equally significant
bAge group should be selected according to the modeling results
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7 Vaccine efficacy and period of 
protection
Vaccine efficacy (VE) is defined as the abil­
ity of a vaccine to prevent the incidence 
of a disease (e. g., HZ) or disease­related 
endpoints (such as PHN) in clinical stud­
ies under optimal and controlled condi­
tions. These conditions are normally met 
in RCTs. Two RCTs were included in the 
systematic review on efficacy of the HZ/su 
inactivated vaccine; these are presented in 
greater detail below [14, 15]. The included 
RCTs had a low risk of bias.
7.1 Zoster efficacy study in persons 
≥ 50 years (ZOE-50)
The ZOE­50 study (ClinicalTrials.gov, 
NCT01165177) was a double blind, place­
bo­controlled multicenter study to verify 
efficacy of the HZ/su inactivated vaccine 
in protecting adults age 50 years and above 
against HZ [15]. The study was conducted 
in 18 countries in Europe, North Amer­
ica, Latin America, and Asia/Australia. 
Participants age 50 years and older were 
recruited at a ratio of 1:1 for the vaccine 
and placebo arms. The following exclu­
sion criteria were applied: a medical his­
tory of HZ, previous vaccination against 
VZV or HZ, immunosuppression owing 
to a disease (e. g., malignoma or HIV in­
fection) or immunosuppressive therapy, 
allergy to one of the components of the 
vaccine, severe existing underlying dis­
ease with a survival time of <4 years, si­
multaneous participation in another clin­
ical trial, administration of another study 
drug (medicinal product or vaccine) with­
in 30 days before study initiation, admin­
istration of immunoglobulins or blood 
products within 90 days before study ini­
tiation, other planned vaccinations within 
30 days before study initiation, and acute 
illness or fever at the time of recruitment. 
Female participants were excluded if they 
were pregnant or nursing or planning to 
become pregnant.
Each study participant received two 
doses of 0.5 mL HZ/su inactivated vac­
cine or placebo (0.9% saline solution) in­
jected i. m. with an interval of 2 months. 
Because the solutions differed in appear­
ance, the injection solution was prepared 
and administered by research assistants 
who were not involved in the assessment 
of the study results in any way. Study par­
ticipants were monitored for a period of at 
least 30 months after receiving the second 
vaccine dose via monthly contacts and an­
nual visits. The primary aim of the study 
was to investigate VE in protecting against 
Fig. 2 8 Efficacy of HZ/su inactivated vaccine in preventing HZ in various age groups (≥50–59 years, ≥60–69 years, ≥70–79 
years, ≥80 years); information from the cumulative follow-up periods (total) in person-years [14, 15]
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HZ from the age of 50 years. The second­
ary aim was to show evidence of efficacy in 
the defined age groups. VE was identified 
as a reduction in the risk of developing 
HZ. Efflorescence suspected as attributa­
ble to HZ occurring after the second vac­
cine dose was examined by the study in­
vestigators. In each suspected case, swabs 
were taken from three lesions to verify 
the HZ diagnosis via PCR. The lower de­
tection limit was 10 VZV DNA copies. If 
no examination material was available for 
laboratory diagnosis, HZ diagnosis was 
made by a five­member team of experts 
based on the clinical picture, photographs 
of the lesions, and disease progression.
Between August 2010 and July 2011, 
a total 16,160 study participants were re­
cruited and stratified according to region 
and age (age groups: 50–59, 60–69, and 
≥70 years). A total 749 participants were 
excluded from the study analysis, mostly 
owing to good clinical practice guideline 
violations. The remaining 15,411 study 
participants were included in the inten­
tion­to­treat (ITT) analysis, 7698 in the 
vaccine arm, and 7713 in the placebo 
arm. The percentage in each age group was 
identical in both arms: 47% of participants 
were 50–59 years old, 29% were age 60–69 
years, and 23% were age 70 years and over. 
The mean age at study initiation was 62.3 
years. Demographic characteristics were 
congruent between the two groups. Most 
participants were from Europe (51.2%), 
white (71.8%), and female (61.2%). The 
mean follow­up period was 3.2 years.
In the ITT analysis, VE in protect­
ing against HZ from the age of 50 years 
was 96.2% (95% CI 93.0–98.0%). HZ in­
cidence in the vaccine arm was 0.4 cas­
es/1000 PY, vastly lower than in the pla­
cebo arm (09.3/1000 PY). The point 
estimates of age­specific VE in protect­
ing against HZ were at a similarly high 
level, but the confidence intervals were 
broader. This is especially true for the two 
highest age groups, as the number of par­
Table 2 (continued)





HZ cases HZ incidence  
cases/1000 PY
Placebo arm HZ cases HZ incidence  
cases/1000 PY
HZ VE (95% CI), %
ZOE-50 (ITT)
50–59 3645 3 0.2 3644 95 7.8 96.9 (90.6–99.4)
60–69 2244 5 0.7 2246 83 10.9 94.1 (85.6–98.1)
≥70 1809 1 0.2 1823 57 10.2 98.3 (89.9–100)
Overall 7698 9 0.4 7713 235 9.3 96.2 (92.7–98.3)
ZOE-50 (modified analysis)
50–59 3492 3 0.3 3525 87 7.8 96.6 (89.6–99.3)
60–69 2141 2 0.3 2166 75 10.8 97.4 (90.1–99.7)
≥70 1711 1 0.2 1724 48 9.4 97.9 (87.9–100.0)
Overall 7344 6 0.3 7415 210 9.1 97.2 (93.7–99.0)
ZOE-70 (ITT)
70–79 5414 22 1.0 5420 181 8.7 88.0 (81.3–92.7)
≥80 1536 8 1.4 1530 59 10.9 86.9 (72.4–94.6)
Overall 6950 30 1.1 6950 240 9.1 87.7 (82.0–92.0)
ZOE-70 (modified analysis)
70–79 5114 17 0.9 5189 169 8.8 90.0 (83.5–94.4)
≥80 1427 6 1.2 1433 54 11.0 89.1 (74.6–96.2)
Overall 6541 23 0.9 6622 223 9.2 89.8 (84.2–93.7)
Pooled analysis ZOE-50 + ZOE-70 (ITT)
70–79 6837 24 0.9 6856 235 8.9 89.9 (84.6–93.7)
≥80 1921 8 1.1 1917 75 11.1 89.7 (78.6–95.8)
Overall 8758 32 1.0 8773 310 9.4 89.9 (85.4–93.2)
Pooled analysis ZOE-50 + ZOE-70 (modified analysis)
70–79 6468 19 0.8 6554 216 8.9 91.3 (86.0–94.4)
≥80 1782 6 1.0 1792 68 11.1 91.4 (80.2–97.0)
Overall 8250 25 0.8 8346 284 9.3 91.3 (86.8–94.5)
Table continues at next page
Table 2 Efficacy of the HZ/su inactivated vaccine against HZ and PHN in the ZOE-50 and ZOE-70 studies and in the pooled cohort, according to 
age groups (ITT and modified analysis) [14, 15]
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ticipants was markedly lower (. Fig. 2; 
. Table 2).
In modified analyses, those study par­
ticipants from the ITT group who did not 
receive a second vaccine dose or who re­
ceived the wrong vaccine or an HZ diag­
nosis fewer than 30 days after the second 
vaccine were excluded. In these modified 
investigation cohorts, VE overall and for 
each age group was slightly higher than 
the levels in the ITT group (. Table 2).
7.2 Zoster efficacy study in persons 
≥ 70 years (ZOE-70)
The ZOE­70 study (ClinicalTrials.gov, 
NCT01165229) was initiated to examine 
the efficacy and safety of the HZ/su inac­
tivated vaccine in protecting against HZ 
and PHN in adults age 70 years and old­
er, and to conduct a pooled analysis with 
the results of the ZOE­50 study [14]. The 
ZOE­70 study was also a double­blind, 
placebo­controlled study conducted at 
the same study centers as the ZOE­50 trial 
and with a study design identical to that of 
ZOE­50 with regard to inclusion and ex­
clusion criteria, randomization, blinding, 
stratification according to age and region, 
and vaccination regimen.
The primary aim of the ZOE­70 study 
was to investigate VE of the HZ/su inac­
tivated vaccine in protecting against HZ 
in people age ≥ 70 years. The pooled ana­
lysis included study participants age ≥ 70 
years from both studies (ZOE­50 + ZOE­
70) and had the primary study aim to ex­
amine VE against both HZ and PHN in 
this age group. The secondary study aim 
of the pooled analysis was to determine 
VE against PHN in adults age ≥ 50 years 
and to evaluate reactogenicity and safety.
The criteria for suspicion and diagnosis 
of HZ were identical to those in the ZOE­
50 study. To monitor the occurrence of 
PHN, all study participants with HZ were 
asked to report to the study center regular­
ly for examination. In addition, they were 
asked to keep a pain diary every day for 28 
days and weekly thereafter, in which they 
documented their pain score, from 0 (no 
pain) to 10 (severest pain). Entries were to 
be completed for at least 90 days after the 
occurrence of HZ efflorescence and until 
the patient was pain free for 4 weeks. PHN 
was defined as pain with a score ≥ 3 that 
continued or developed more than 90 days 
after the occurrence of rash.
A total of 14,816 study participants 
were recruited between August 2010 and 
July 2011. A total of 916 participants were 
excluded from the study analysis, mostly 
owing to good clinical practice guideline 
violations. The remaining 13,900 study 
participants were included in the (ITT) 
analysis, 6950 each in the vaccine and 
placebo arm. The demographic attributes 
between the vaccine and placebo arms of 
the ZOE­70 study corresponded roughly 
with one another. Most participants were 
from Europe (55%), white (76.9%), and 
female (54.9%). The mean age of partic­
ipants in the ZOE­70 study at study initi­
ation was 75.6 years (range: 62–96 years). 
In total, 3066 participants were ≥80 years 
old (22.1%) and 76 participants were ≥90 
years old (0.5%). The mean follow­up pe­
riod was 3.7 years.
In the ITT analysis of the ZOE­70 
study, VE in protecting against HZ was 
87.7% (95% CI 82.0%–92.0%). HZ in­
cidence in the vaccine arm was 1.1 cas­
es/1000 PY, vastly lower than in the place­
bo arm (09.1/1000 PY). VE in protecting 
against HZ was nearly the same in the dif­
ferent age groups (. Table 2). Here as well, 
VE was somewhat higher in the modified 
cohorts than in the ITT group (. Table 2).
In total, 17,531 participants from the 
ZOE­50 and ZOE­70 studies were includ­
Table 2 (continued)







PHN incidence  
cases/1000 PY
Placebo arm PHN cases PHN incidence 
cases/1000 PY
PHN VE (95% CI), %
Pooled analysis ZOE-50 + ZOE-70 (ITT)
50–59 3644 0 0.0 3642 9 0.6 100 (49.1–100)
60–69 2243 0 0.0 2245 3 0.3 100 (–145.2–100)
70–79 6837 4 0.1 6856 31 1.2 87.0 (63.3–96.7)
≥80 1921 4 0.6 1917 7 1.0 43.0 (–124.3–87.8)
≥50 overall 14645 8 0.1 14660 50 0.9 83.9 (65.8–93.5)
≥70 overall 8758 8 0.2 8773 38 1.1 78.9 (54.0–91.5)
Pooled analysis ZOE-50 + ZOE-70 (modified)
50–59 3491 0 0.0 3523 8 0.6 100 (40.8–100)
60–69 2140 0 0.0 2166 2 0.2 100 (–442.9–100)
70–79 6468 2 0.1 6554 29 1.2 93.0 (72.4–99.2)
≥80 1782 2 0.3 1792 7 1.1 71.6 (–51.6–97.1)
≥50 overall 13881 4 0.1 14035 46 0.9 91.2 (75.9–97.7)
≥70 overall 8250 4 0.1 8346 36 1.2 88.8 (68.7–97.1)
HZ herpes zoster, PHN postherpetic neuralgia, PY person-years, VE vaccine efficacy, ITT intention-to-treat, CI confidence interval. ITT all participants successfully recruited 
and included according to protocol, and received at least one vaccination. Modified analysis exclusion of participants who either did not receive a second vaccine dose or 
who received the wrong vaccine or a confirmed HZ diagnosis less than 30 days after the second vaccine dose.
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ed in the pooled analysis of participants 
age ≥70 years. In this population as well, 
the demographic attributes were similar in 
the comparison groups.
In the pooled ITT analysis from the 
ZOE­50 and ZOE­70 studies, VE in pro­
tecting against HZ for adults age ≥70 years 
was 89.9% (95% CI 85.4–93.2%); there 
was no difference between the age groups. 
In the modified analysis, VE for adults age 
≥70 years was over 91.3% (95% CI 86.8–
94.5%) (. Table 2).
Over a period of 3.7 years after vacci­
nation, VE in protecting against PHN in 
the pooled ITT analysis was 83.9% (95% 
CI 65.8–93.5%) for individuals age ≥50 
years and 78.9% (95% CI 54.0–91.5%) for 
those age ≥70 years. Because of the low 
number of PHN cases observed in the in­
dividual age groups, the confidence inter­
vals for the point estimates in the results 
of VE were very wide and/or included 1 
(. Fig. 3; . Table 2).
7.3 Results of the meta-analysis of 
data from the ZOE-50 and ZOE-70 
studies on the efficacy of the HZ/
su inactivated vaccine in protecting 
from HZ and PHN
Data from the ITT groups were analyzed 
in the meta­analysis of age­specific efficacy 
against HZ of the HZ/su vaccine (. Fig. 2). 
For the age groups ≥70 years, pooled re­
sults of the ZOE­50 and ZOE­70 studies 
were used for the analysis. The meta­anal­
ysis showed a VE across all age groups of 
92.0% (95% CI 89.0–94.0%). The point es­
timates of VE declined somewhat with in­
creasing age, from 97% in participants age 
50–59 years to 94% in those age 60–69 
years and 90% in the age groups 70 years 
and older; the confidence intervals around 
the point estimates were overlapped.
Based on the meta­analysis, the effica­
cy against PHN was 82.0% (95% CI 64.0–
91.0%) across all age groups. Considering 
the efficacy in the various age groups, sig­
nificant vaccine protection was seen only 
in those 70–79 years old, with 87.0% (95% 
CI 63.0–95.0%) (. Fig. 3). In the young­
er age groups and in those over 80 years 
old, the study populations were too small 
for this rare event. No clear assessment 
was possible because of the low number 
of cases observed. The confidence inter­
vals were wide in all age groups, and some 
included 1.
7.4 Duration of protection from HZ 
provided by the HZ/su inactivated 
vaccine (results of the pooled 
analysis of the ZOE-50 and ZOE-70 
studies)
Because the incidence of HZ increases 
with age, long­term protection provided 
by the vaccine is especially important. For 
the duration of vaccine protection against 
HZ, only data for adults age ≥70 years 
Fig. 3 8 Efficacy of HZ/su inactivated vaccine in preventing postherpetic neuralgia in various age groups (≥50–59, ≥60–69, 
≥70–79, and ≥80 years); data from the cumulative follow-up periods (total) in person-years [14]
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from the pooled analysis of the ZOE­50 
and ZOE­70 studies over a time frame of 
4 years were available [14]. The data were 
from the modified analysis, i. e., partici­
pants who did not receive the second vac­
cine dose or who developed HZ within 30 
days after the second vaccine dose were 
excluded. Based on the pooled analysis, 
VE in protecting against HZ dropped af­
ter administration of the second vaccine 
dose, from 97.6% (95% CI 90.9–99.8%) in 
the first year to <90% from the third year 
after vaccination (. Fig. 4). The data from 
years 3 and 4 after vaccination suggest that 
VE reaches a constant plateau as time pro­
gresses. A clear interpretation based on 
clinical data is not possible at this time. No 
data have been published on the duration 
of action of the HZ/su inactivated vaccine 
in protecting against PHN.
7.5 Long-term immunogenicity of 
the HZ/su inactivated vaccine
Because the duration of vaccine efficacy 
could be examined for only a short peri­
od of time in the RCTs, data from a sin­
gle­arm phase II multicenter study were 
referenced in addition to the systemat­
ic review. In that study, the immune re­
sponse of participants age ≥60 years who 
had received two HZ/su vaccinations at a 
2­month interval was examined [16, 17]. 
A total of 129 participants from Czech 
Republic, Germany, and the Netherlands 
were enrolled. The cellular and humoral 
immune responses induced by vaccina­
tion were examined annually over a peri­
od of 6 years. The frequency of gE­specif­
ic CD4+ T cells with at least two expressed 
activation markers and the geometric 
mean values of the serum concentration 
(GMC) of anti­gE antibodies (mlU/mL) 
were determined using an ELISA devel­
oped by the vaccine manufacturer (cut­
off: 18 mIU/mL). The subgroup of par­
ticipants from Czech Republic (n = 68) 
was followed up for a period of 9 years 
[18]. The median frequency of gE­specif­
ic CD4+ T cells was highest 3 months after 
the second vaccine dose (1800/106 cells). 
This proportion dropped to 415/106 cells 
during the 9 years after vaccination, but 
at that point it was still more than three 
times higher than pre­vaccination lev­
els (119/106) (. Fig. 5). The data indicate 
that the duration of vaccine­induced pro­
tection may be even longer than that con­
firmed to date in RCTs.
The highest mean concentration of 
anti­gE antibodies was also measured 3 
months after administration of the second 
vaccine dose (43,100 mIU/mL), which 
declined as time progressed. However, 
in year 9 after the second vaccine dose, it 
was still seven times higher than pre­vac­
cination levels (. Fig. 6). From the year 
4 after completing the vaccination series, 
the frequency of gE­specific CD4+ T cells 
and the concentration of anti­gE antibod­
ies remained at constant high levels. This 
observation fit with the VE findings ac­
cording to clinical endpoints, which re­
mained at a steady level 3 and 4 years af­
ter vaccination.
7.6 Conclusions on the efficacy and 
effectiveness of the HZ vaccination
The HZ/su inactivated vaccine can effec­
tively prevent HZ in people >50 years; ef­
ficacy is 92% across all age groups. Pro­
tection against HZ falls slightly with 
increasing age but remains over 90% in 
adults 70 years and over. Thus, the HZ/
su inactivated vaccine confers a high level 
of protection at all ages and also in older 
people with the highest risk of HZ. This is 
an advantage compared with the live at­
tenuated vaccine, which has a markedly 
lower VE in older age groups. Protection 
drops from 98% in the first year to 85% 
in the third year after vaccination and re­
mains at 88% in the fourth year after vac­
cination. Further conclusions on the dura­
tion of protection for the clinical endpoint 
HZ are not yet possible. Based on immu­
nological data available for a period of 9 
years after vaccination, the immune re­
sponse remains at a level that is multi­
ple times higher than before vaccination. 
This might indicate a prolonged duration 
of vaccine­induced protection. The HZ/su 
inactivated vaccine can prevent the occur­
rence of PHN. This effect is derived from 
the effective prevention of HZ as a precon­
dition for the prevention of its sequelae. 
Because of the rarity of this event, signifi­
cant results on protection against PHN are 
available only for the entire cohort, and 
age­related results are available only for 
the largest cohort recruited, participants 
age 70–79 years. Overall, VE is 82%, and it 
is 87% among 70­ to 79­year­olds.
8 Vaccine reactogenicity and 
safety
8.1 Approach and studies 
considered
The STIKO working group assessed se­
vere adverse drug reactions (8 points) 
and severe pain at the point of injection 
(7 points) as essential endpoints. Fever 
as a systemic reaction was classified as 
an important endpoint (5 points); swell­
ing and other local reactions were consid­
ered less important endpoints (3 points) 
(. Table 1).
Results from three RCTs that record­
ed the abovementioned endpoints were 
Fig. 4 9 Duration of 
efficacy of the HZ/su 
inactivated vaccine 
in preventing HZ in 
adults ≥70 years old 
(ZOE50 + ZOE70) [14]
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included in the safety evaluation. These 
RCTs were the ZOE­50 [15] and ZOE­70 
studies [14], described in subsections 7.1 
and 7.2 above, and results from two study 
arms of a phase II study [19]. The included 
RCTs had a low risk of bias. Details on the 
studies and results of the aggregate evalu­
ation are presented hereinafter.
One subgroup of participants from the 
ZOE­50 study was asked to document lo­
cal reactions at the site of injection (pain, 
redness, and swelling) and systemic reac­
tions (fatigue, fever, headache, and myal­
gia) in a diary for 7 days [15]. This sub­
group included all participants age ≥ 70 
years and selected randomized partici­
pants from younger age groups. Redness 
and swelling at the injection site were as­
sessed using diameter on a scale from 0 
(<20 mm) to 3 (>100 mm). Fever, prefer­
ably measured orally, was also assessed us­
ing a 4­point scale from 0 (<37.5 °C) to 3 
(>39.0 °C). For other side effects intensi­
ty was classified on a scale from 0 (none) 
to 3 (common everyday activities are im­
possible). Other adverse side effects were 
registered as spontaneous reports for a pe­
riod of 30 days after every vaccine dose. 
Other severe side effects were measured 
for a period of at least 12 months after ad­
ministration of the second dose. All health 
complaints with any link to the study, all 
deaths, and all potentially immune­me­
diated discomfort were evaluated for the 
entire study duration of 3.5 years. A to­
tal of 8926 participants were included in 
the subgroup for safety evaluation of the 
HZ/su inactivated vaccine (4460 from the 
vaccine and 4466 from the placebo arms).
In the ZOE­70 study, a random sam­
ple group of 1025 participants (7.4% of the 
total study population; 512 from the vac­
cine arm and 513 from the placebo arm) 
was recruited from among the study par­
ticipants in the safety evaluation [14]. The 
evaluation procedure was identical to that 
of the ZOE­50 study; the study duration 
was 4 years.
In a multi­arm, phase II multicenter 
study, the safety of the HZ/su inactivat­
ed vaccine in various doses was tested 
among participants age ≥50 years [19]. 
The study included a total of 410 partici­
pants from Czech Republic, Spain, and the 
United States (US). Data from the placebo 
arm (n = 38) and the arm with a later vac­
cine concentration (n = 150) were extract­
ed. The safety evaluation was identical to 
that of the ZOE­50 and ZOE­70 studies. 
Every major event over a time frame of 14 
months was evaluated.
8.2 Local reactions after the HZ/su 
inactivated vaccine
In clinical studies of the safety of the HZ/su 
inactivated vaccine, participants in the vac­
cine arm reported local reactions at the site 
of injection significantly more frequently 
than participants in the placebo arm (81% 
vs. 12%). Pain was the most frequent lo­
cal reaction. Local reactions of the highest 
intensity (grade 3) occurred in 9.4% ver­
sus 0.3% of participants (. Fig. 7). The fre­
quency of vaccine reactions was not sig­
nificantly increased after administration 
of the second vaccine dose [14]. Vaccine 
reactions were independent of age; 53% 
of participants age ≥80 years and 55% of 
those age 70–79 years reported vaccine re­
actions [14]. All reactions were temporary 
and lasted a median of 2–3 days.
8.3 Systemic reactions after the HZ/
su inactivated vaccine
Systemic side effects associated with the 
vaccine were also more frequent in the in­
tervention arm (65%) than in the place­
bo arm (29%). Systemic reactions of the 
highest intensity (grade 3) occurred in 
10.6% of participants in the vaccine arm 
and 2.4% of those in the placebo arm 
(. Fig. 8). The frequency of the systemic 
reactions fever, fatigue, myalgia, and head­
ache were described in the ZOE­70 study, 
each with regard to intensity and for grade 
3 (see the appendix).
8.4 Severe adverse events caused 
by the vaccine (SAE)
In the three clinical trials examining the 
safety of the HZ/su inactivated vaccine, 24 
of 29,499 participants experienced SAEs 
in connection with the vaccine, of which 
Fig. 5 9 Median and 
95% confidence inter-
vals of the frequency 
of VZV glycoprotein E 
(gE)-specific CD4+ T 
cells over 108 months 
[16–18]
Fig. 6 9 Geometric 
mean values of serum 
concentration (GMC) 
of anti-gE antibodies 
(mlU/mL) with 95% 
confidence intervals 
over 108 months 
[16–18]
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13 occurred in the vaccine arm and 11 in 
the placebo arm (. Fig. 8). The following 
syndromes were recorded as SAEs in the 
vaccine arm: hypotension with syncope, 
lymphadenitis, myocardial infarction, ul­
cerative colitis, pancreatitis, erythema and 
pain at the injection site, shivering, fever, 
allergic granulomatous vasculitis, bacterial 
joint inflammation, erysipelas, HZ oticus, 
eczema, neutropenic sepsis, and acute my­
eloid leukemia (for details, see appendix).
SAEs that were considered by the re­
sponsible reviewers to be related to inter­
vention, potentially immune­mediated 
diseases, and deaths occurred with com­
parable frequency in the study arms (vac­
cine and placebo arm) of the ZOE­50 and 
ZOE­70 studies (. Fig. 9).
The reviewers initially classified one 
death in the HZ/su arm of the ZOE­70 
study as associated with the vaccine. This 
case occurred in a 90­year­old participant 
with preexisting thrombocytopenia who 
was diagnosed with acute myeloid leu­
kemia (AML) 75 days after the first dose 
of HZ/su and died from neutropenic sep­
sis 97 days after vaccination, without hav­
ing received the second dose. The CHMP 
(Committee for Medicinal Products for 
Human Use) considered a relationship be­
tween vaccination and AML to be high­
ly unlikely as the neutropenic sepsis and 
subsequent events were considered most 
likely side effects of ongoing therapy with 
azacitidine [20].
8.5 Conclusions on the safety of the 
HZ/su inactivated vaccine
The HZ/su inactivated vaccine is excep­
tionally reactogenic. Local reactions and 
grade 3 systemic reactions occurred in 
roughly every 10th vaccinated person. 
However, the vaccine reactions do not last 
long (1 to 2 days for reactions of the highest 
degree). In marketing authorization stud­
ies, there were no warnings about severe 
side effects or potentially immune­medi­
ated diseases. The frequency of SAEs was 
the same in the vaccine group and in the 
placebo group. SAEs considered to be vac­
cine related mainly included health con­
ditions or diseases that are generally not 
rare in the investigated age groups. One 
fatal case was initially regarded as vaccine 
related, but the CHMP deemed a causal 
relationship to be unlikely.
9 Evidence profile of the 
efficacy and safety of the HZ/su 
inactivated vaccine
To assess the quality of available evidence 
for the efficacy and safety of the HZ/su in­
activated vaccine, an evidence profile was 
drawn up of pre­defined PICO questions 
using GRADEprofiler software. Relevant 
effect estimates observed for each end­
point and the quality of evidence for these 
estimators have been compiled in this pro­
file (. Table 3).
The quality of evidence for efficacy of 
the HZ/su inactivated vaccine in prevent­
ing HZ is classified as high; the quality of 
evidence for efficacy against PHN is clas­
sified as low, and the quality of evidence 
for the safety of the vaccine is estimated 
as moderate.
10 Implementing the HZ/su 
vaccination
10.1 Dose, type, and duration of 
administration
The HZ/su vaccine is approved for use in 
adults age 50 years and older. The vacci­
nation scheme is two i. m. vaccinations at 
least 2 months apart. In addition to the 
vaccination interval of 2 months, immu­
nogenicity studies have also examined 
vaccination intervals of 6 and 12 months 
and determined the vaccine response rates 
1 month after administering the second 
dose in each case [21]. It was shown that 
the immune response to vaccination on a 
Fig. 7 8 Forest plots of relative risks (RR) of local reactions to the HZ/su inactivated vaccine (all degrees and grade 3). a Local 
reactions at the injection site (all degrees), b Local reactions at the injection site (grade 3)
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0–6 month schedule was the only one not 
inferior to the 0–2 month schedule. Based 
on these findings, administration of the 
second vaccine dose can be delayed for 
up to 6 months without concern about a 
loss in the target immune response. If ad­
ministration of the second vaccine dose is 
delayed for more than 6 months, the im­
mune response appears to be somewhat 
reduced, but study data show that anti­gE 
antibody concentrations are more than 11 
times higher than pre­vaccination levels. 
No study data are available regarding the 
need for booster doses or repeated vacci­
nations. Results from long­term observa­
tions on the duration of protection after 
vaccination are required, ideally with the 
clinical endpoint of HZ.
10.2 Coadministration with other 
vaccines
The immunogenicity and safety of the HZ/
su inactivated vaccine with simultaneous 
administration of a quadrivalent season­
al influenza vaccine (QIV) were studied 
in an open, randomized phase III trial in 
adults age ≥50 years. Participants (n = 828) 
Fig. 8 8 Forest plots of the relative risks (RR) of adverse systemic side effects to the HZ/su inactivated vaccine (all degrees and 
grade 3). a Systemic adverse side effects (all degrees), b Systemic adverse side effects (grade 3)
Fig. 9 8 Forest plots of the relative risks (RR) for severe adverse effects of the HZ/su inactivated vaccine and possible 
immune-mediated diseases. a Possible vaccination-related severe adverse effects, b Possible immune-mediated diseases
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were allocated to one of two groups at a 
ratio of 1:1. Participants received the first 
HZ/su inactivated vaccine dose together 
with the QIV dose, followed by a second 
HZ/su dose 2 months later (intervention 
arm), or the QIV first and the two HZ/su 
inactivated vaccine doses 2 and 4 months 
later (control arm). According to meas­
ured anti­gE concentrations (cut­off: 97 
mIU/mL), a similar number of partic­
ipants in the intervention arm (95.8%, 
95% CI 93.3–97.6%) and the control arm 
(97.9%, 95% CI 96.0–99.1%) responded 
to the HZ/su inactivated vaccine. At the 
same time, it could be demonstrated that 
the antibody concentrations to the HZ/
su and QIV vaccines were not inferior to 
those in the control arm. Safety concerns 
regarding simultaneous administration 
were not observed [22]. Simultaneous 
administration of the HZ/su inactivated 
vaccine and a non­adjuvanted, inactivat­
ed, seasonal influenza vaccine on different 
limbs is possible, according to the product 
information.
Simultaneous administration of the 
HZ/su inactivated vaccine with the 23­va­
lent pneumococcal polysaccharide vac­
cine (PPSV23) was studied in 865 adult 
participants age 50 years and older (aver­
age age 63.2 years) in an open randomized 
trial [23]. Here as well, participants were 
assigned to the coadministration or con­
trol arm at a ratio of 1:1, and the vaccina­
tion scheme in both arms corresponded 
to that of the study on the simultaneous 
administration of QIV. In total, 98% of 
participants in both arms responded to 
the HZ/su inactivated vaccine, and sim­
ilar antibody concentrations were meas­
ured. No safety concerns arose in this 
study either. The study results were not 
taken into account in the current valid 
version of the product information (last 
updated in March 2018), and coadmin­
istration is not yet covered by marketing 
authorization.
10.3 HZ/su vaccination after prior 
HZ disease
The immunogenicity and safety of the 
HZ/su inactivated vaccine in patients ≥50 
years after prior HZ disease were studied 
in a non­randomized, open, multicenter 
trial in Canada and Russia between June 
2013 and November 2014 [24]. Among 
participants in the study (n = 96), 68% 
(n = 65) had developed HZ within the 
past 4 years and none had ongoing active 
symptoms; in 19% (n = 18) of participants, 
the HZ episode occurred 5–9 years earli­
er and in 14% (n = 13), it was 10 or more 
years earlier. The median participant age 
was 64 years (range: 50–89 years). Partic­
ipants received two doses of HZ/su at an 
interval of 2 months and were observed 
for a follow­up period of 12 months. Im­
munogenicity of the vaccine was meas­
ured as the rise in titer of anti­gE antibod­
ies 1 month after the second vaccination. 
The primary goal of the study was a four­
fold increase in titer over baseline before 
vaccination; this was achieved in 90.2% 
(95% CI 81.7–95.7%) of participants. Lo­
cal and systemic side effects were docu­
mented for 7 days and adverse events for 
30 days after each vaccination. Severe 
side effects occurring at any time dur­
ing the study were recorded. The results 
confirmed the findings of the marketing 
authorization studies. With nine HZ ep­
isodes reported by six participants over 
a period of 12 months after vaccination, 
more recurrent episodes occurred than 
expected based on observational studies 
in unvaccinated people with anamnes­
tic HZ. However, the HZ diagnoses were 
not confirmed by laboratory investiga­
tion and three patients had not consulted 
a physician. In summary, it can be stated 
that the HZ/su inactivated vaccine disease 
is sufficiently immunogenic in adults age 
≥ 50 years with prior HZ, and no safety 
concerns have been identified.
10.4 HZ/su vaccination after prior 
HZ live vaccine
An open, multicenter phase III study was 
conducted to investigate whether the im­
mune response to the HZ/su inactivated 
vaccine in adults age ≥ 65 years who had 
been vaccinated with the live HZ vac­
cine 5 or more years previously is com­
parable to that in previously naive indi­
viduals [25]. The study was conducted in 
the US between March and August 2016, 
with 430 study participants allocated to 
one of the two groups at a ratio of 1:1. 
In parallel, the tolerability of HZ/su vac­
cination after prior HZ live vaccine was 
studied; safety monitoring was conduct­
ed through August 2017. The aim of the 
study was to compare the humoral im­
mune response to the two vaccination 
regimens 1 month after the second vac­
cine dose using the GMC of anti­gE anti­
bodies, and to demonstrate non­inferior­
ity of the previously vaccinated group to 
the naive group. Among participants pre­
viously vaccinated with the live vaccine, 
the humoral immune response to the HZ/
su inactivated vaccine was not worse than 
the response among those not previously 
vaccinated. There was also no difference 
between the groups in cellular immu­
nogenicity, reactogenicity, or safety [25]. 
Based on these findings, there are no ob­
jections to use of the HZ/su inactivated 
vaccine in people previously vaccinated 
with the live vaccine, as long as there is 
an interval of at least 5 years between the 
two vaccinations.
10.5 HZ/su vaccination in patients 
with bleeding tendency
The HZ/su inactivated vaccine is approved 
for i. m. injection. In an open, randomized 
phase III trial (participant ratio 1:1), the 
safety and immunogenicity of subcutane­
ous (s. c.) injection were compared to that 
of i. m. injection in two vaccinations (at 0 
and 2 months) [26]. A total of 60 partici­
pants from Japan age ≥ 50 years were in­
cluded. The age distribution was identi­
cal in the two groups, with mean age 61.9 
years; 50% of participants were female. 
Anticipated and unanticipated reactions 
after administration of the vaccine were 
documented for 7 and 30 days after vac­
cination, and their severity was assessed 
according to grades 1 to 3. Although the 
immune response after vaccination was 
equally high in both groups, the reacto­
genicity of the vaccine in the s. c.­vacci­
nated group was markedly stronger than 
that in the i. m. group. According to the 
product information, the HZ/su inactivat­
ed vaccine is approved only for i. m. ad­
ministration.
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10.6 HZ/su vaccination in patients 
with immunosuppression and 
other underlying diseases
10.6.1 Patients after autologous 
stem-cell transplantation
In the first year after hematopoietic stem­
cell transplantation (HSCT), the risk of 
developing HZ is markedly higher [27] 
and HZ disease can be complicated by 
visceral dissemination [28]. The safety 
and immunogenicity of the HZ/su in­
activated vaccine were studied in an ob­
server­blinded, placebo­controlled phase 
1/2a trial between 2009 and 2012 in the 
US among individuals who had received 
an autologous stem­cell transplant 50–70 
days previously [29]. The 121 study par­
ticipants were randomized at a ratio of 
1:1:1:1 and received either three doses 
gE/ASO1B (later vaccine), or three doses 
gE/ASO1E, or one dose physiological sa­
line solution and two doses gE/AS01B, or 
three doses physiological saline solution, 
at months 0, 1, and 3. Regardless of the 
vaccine formula, the gE­specific CD4+ cell 
counts and anti­gE serum antibody titers 
1 month after the last vaccine dose were 
both higher than those in the placebo 
arm, and titer levels remained constant­
ly high for 1 year. Both vaccine formulas 
were well tolerated and triggered a satis­
factory immune response that remained 
for a period of 1 year.
The efficacy and safety of the HZ/su 
inactivated vaccine in patients after au­
tologous HSCT were also studied for 21 
months in a randomized, observer­blind­
ed, placebo­controlled phase 3 trial strati­
fied into two age groups (18–49 years and 
≥50 years) [30]. In total, 1721 (93.2%) 
of the 1846 participants vaccinated after 
HSCT were included in the analysis. The 
efficacy against HZ was 68%, and 89% 
against PHN; this was the same for both 
age groups. There were no safety concerns.
HZ and PHN can be effectively pre­
vented with the HZ/su inactivated vac­
cine in patients after autologous HSCT, 
regardless of age.
10.6.2 Persons with HIV
People with HIV have a markedly higher 
risk of developing HZ [31, 32]. Antiret­
roviral therapy (ART) clearly reduces the 
risk of HZ, but it is still 3–5 times high­
er than in people with healthy immune 
systems [33]. The safety and immuno­
genicity of the HZ/su inactivated vac­
cine were studied in an observer­blind­
ed, placebo­controlled phase 1/2a trial in 
Germany, the US, and the UK between 
September 2010 and May 2013 [34]. The 
following three groups of patients with 
HIV were studied; participants differed 
with regard to immune status (CD4+ cell 
count) and ART: (i) ART and CD4+ cell 
count ≥ 200 cells/mm3 (n = 95); (ii) ART 
and CD4+ cell count < 200 cells/mm3 
(n = 14), (iii) no ART and CD4+ cell count 
≥ 500 cells/mm3 (n = 15). The groups were 
randomized at a ratio of 3:2 and received 
the HZ/su inactivated vaccine or saline 
solution at months 0, 2, and 6. Of the 
123 enrolled participants (average age 46 
years), 112 (91.1%) completed the study. 
Local and systemic reactions occurred in 
the vaccine arm more frequently than in 
the placebo arm, but generally did not last 
long (median: 1–3 days) and were mild 
to moderate in intensity. Up to 16.4% of 
participants in the vaccine arm and 8.3% 
of those in the placebo arm complained 
of severe (grade 3) local or general reac­
tions. SAEs were not observed. Over a 
follow­up period of 18 months, the vac­
cine showed no sustained negative ef­
fects on HIV viral load or immune sta­
tus (measured by CD4+ cell count). One 
month after the third vaccine dose, the 
gE­specific cell­mediated immune re­
sponse and anti­gE serum antibody ti­
ter were significantly higher in the ver­
um group than in the placebo group, and 
remained higher than pre­vaccination 
titers for a period of 12 months. Based 
on the study results, the HZ/su vaccine is 
sufficiently immunogenic in people with 
HIV and has an acceptable safety pro­
file. Because the gE­specific, cell­medi­
ated immune response barely increases 
after the third vaccine dose, a two­dose 
scheme is deemed sufficient for success­
ful vaccination.
10.6.3 Patients with tumors
Patients with solid tumors who are re­
ceiving immunosuppressive therapy have 
a fourfold greater risk of developing HZ. 
In a randomized, observer­blinded, place­
bo­controlled phase 2/3 study, the immu­
nogenicity and safety of the HZ/su inacti­
vated vaccine were studied in patients 18 
years and over (n = 347) receiving immu­
nosuppressive therapy for a tumor disease 
in Canada, Czech Republic, Korea, France, 
the UK, and Spain [35]. Participants in the 
vaccine and placebo arms (1:1) were allo­
cated into two further subgroups (each at 
a ratio of 4:1) who received two vaccine 
doses i. m. at an interval of 1–2 months. 
The first dose was administered either 
8–30 days before starting the chemother­
apy cycle (group A, pre­chemo) or at the 
start of the chemotherapy cycle (group 
B, on chemo). One month after the sec­
ond vaccine dose, the vaccine induced a 
robust immune response regardless of 
whether vaccination started before or at 
the same time as the chemotherapy cycle. 
The immune response persisted for up to 
12 months after the second dose. The vac­
cine was well tolerated, and there were no 
safety concerns.
In another 1:1 randomized, place­
bo­controlled, observer­blinded phase 3 
trial, the safety and immunogenicity of the 
HZ/su inactivated vaccine were studied in 
patients ≥18 years (n = 562) with tumors of 
the lymphatic system (multiple myeloma, 
Hodgkin lymphoma, chronic lymphocytic 
leukemia, non­Hodgkin lymphoma) [36]. 
Participants received two doses at an in­
terval of 1–2 months ≥ 10 days before or 
after chemotherapy. A total of 562 partic­
ipants were included (HZ/su group: 283; 
placebo group: 279). The preliminary re­
sults showed that vaccination induces ro­
bust humoral (anti­gE antibodies) and cel­
lular (gE­specific CD4+ T cells) immunity. 
No safety concerns arose up to 6 months 
after administration of the second dose 
in an ongoing study with blinding main­
tained.
10.6.4 Patients after kidney 
transplant
As a result of lifelong immunosuppres­
sive therapy, people who have received 
a kidney transplant have a sevenfold 
higher risk of developing HZ. In a ran­
domized, double­blind, placebo­con­
trolled phase 3 trial, the immunogenic­
ity and safety of the HZ/su inactivated 
vaccine were studied in individuals who 
had received a kidney transplant in Bel­
gium, Canada, Czech Republic, Finland, 
Italy, Panama, Korea, Spain, and Taiwan 
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in two different age cohorts (18–49 years 
and 50+ years) [37]. Participants (n = 123 
in the vaccine arm and n = 132 in the pla­
cebo arm) received two vaccinations i. m. 
at an interval of 1–2 months, adminis­
tered 4–8 months after transplantation. 
Preliminary data showed that the HZ/
su inactivated vaccine induces a robust 
humoral and cell­mediated immune re­
sponse up to 1 month after the second 
vaccination. The humoral immune re­
sponse was higher in the younger age 
cohort than in the cohort age 50 years 
and over. There were no safety concerns 
up to 1 month after administration of the 
second dose.
10.6.5 Summary of HZ/su 
vaccination in patients with 
immunosuppression and 
underlying diseases
Depending on their underlying disease 
and/or therapy, patients with immuno­
suppression have a markedly increased 
risk of HZ and subsequent PHN. In vac­
cine studies, the efficacy, immunogenic­
ity, and safety of the HZ/su inactivated 
vaccine have been examined in the fol­
lowing risk groups: patients after HSCT, 
people infected with HIV, kidney trans­
plant recipients, patients with tumors 
of the lymphatic system before or after 
immunosuppressive chemotherapy, and 
patients with solid tumors before or af­
ter immunosuppressive chemotherapy. 
In patients after HSCT, the HZ/su inac­
tivated vaccine demonstrated efficacy of 
64–69% in protecting against HZ and 84–
90% in protecting against PHN. In other 
patient groups, vaccination induced ro­
bust humoral and cellular immune re­
sponses that lasted more than 12 months. 
The vaccine is reactogenic, generally 
well tolerated, and there is no evidence 
of SAEs in this patient group. According 
to the product information, the vaccine 
is not contraindicated for patients with 
immunosuppression. It must be noted 
that, as with other vaccines, it is possi­
ble that these patients may not achieve a 
sufficient immune response. An individ­
ual risk­benefit assessment before vacci­
nation is advised [9].
In light of the examined efficacy and 
safety of the HZ/su inactivated vaccine 
in particularly vulnerable groups of pa­
tients with an impaired immune system, 
it can be assumed that the vaccine is safe 
and effective for people with chronic un­
derlying diseases who also have an in­
creased risk of HZ disease and compli­
cations. This is supported by the results 
of a post­hoc analysis using data of the 
pooled ZOE­50 and ZOE­70 trials con­
ducted in patients with underlying dis­
eases such as arthritis, chronic renal dis­
ease, chronic obstructive pulmonary 
disease, coronary disease, and diabetes 
mellitus. In these patients, the analysis 
showed an efficacy level of the vaccine 
that corresponds to the overall efficacy 
against HZ [9, 20].
11 Acceptance and feasibility of 
the HZ/su vaccination
Acceptance of a vaccine in the target 
population is an important prerequisite 
for the successful implementation of a 
new vaccination recommendation. For 
an individual decision on HZ vaccina­
tion, it is necessary to be aware of HZ 
disease, to be able to estimate the severi­
ty of the disease, and to know that there 
is a vaccine that can provide protection 
from the disease. A survey was con­
ducted among people age over 50 years 
(n = 1001) in Italy from October 2014 to 
April 2015 [38]. A total of 95% of partici­
pants said they were aware of HZ disease. 
Most respondents (80%) knew a person 
who had had HZ in the past, and 22% 
had already had HZ themselves. A to­
tal 91% did not know that there is a vac­
cine to prevent HZ, and 85% said that 
they were generally in favor of HZ vac­
cination. This study proved the decisive 
role of primary care physicians in the 
decision­making process for HZ vacci­
nation; 83% of survey respondents said 
they would receive vaccination if their 
primary care physician recommended 
it. The authors of a systematic review on 
the acceptance of HZ vaccination came 
to a similar conclusion [39]. According 
to the review, recommendation by a pri­
mary care physician is the decisive fac­
tor in high acceptance of a vaccine. Ad­
ditional factors identified for successful 
vaccine implementation were cost reim­
bursement and awareness about HZ in 
the target population.
To estimate the implementation of 
vaccination recommendation in the tar­
get group of adults age 60 years and over 
in Germany, data were referenced on sea­
sonal influenza vaccination coverage from 
invoicing data by the associations of stat­
utory health insurance physicians [40] as 
well as data on the use of pneumococcal 
vaccines for older adults from the Ger­
man health interview and examination 
survey for adults (DEGS) [41]. According 
to these data, nationwide influenza vacci­
nation coverage has fallen from around 
48% among people age ≥ 60 years during 
the 2008/09 and 2009/10 seasons to less 
than 35% in the 2016/17 season. Vacci­
nation coverage appears to have stagnat­
ed since the 2012/2013 season at around 
one­third of all adults age 60 years and 
older who are vaccinated for seasonal in­
fluenza. The large spread among the fed­
eral states was also noteworthy (2016/17: 
19.9% in Baden­Württemberg to 55.2% in 
Saxony­Anhalt). Based on the DEGS sur­
vey, 31.4% of people age 65–79 years were 
vaccinated against pneumococcal disease 
in 2008–2011, women (33.2%) somewhat 
more frequently than men (29.3%). How­
ever, it remains unclear at this time wheth­
er these utilization data can be applied to 
HZ vaccination.
12 Modelling the influence of 
the vaccination on HZ and PHN 
epidemiology in Germany
12.1 Methods
A static Markov cohort model was used 
for analysis [42], updated specifical­
ly with regard to data on vaccine effica­
cy and vaccine­induced period of protec­
tion [43]. The model follows a simulated 
cohort of one million 50­year­olds to the 
end of their lives. It covers five conditions 
(health, death, HZ, PHN, and health after 
illness), and calculates a cycle length of 3 
months based on duration of HZ illness 
and PHN definition. The age at vaccina­
tion was varied between 50 and 80 years 
in 5 year steps. In addition to the number 
of HZ (PHN) cases prevented by vaccina­
tion and the number needed to vaccinate 
(NNV) to prevent one HZ (PHN) case, 
health economics analyses were also con­
ducted. Incremental cost­effectiveness ra­
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tios (ICER), with € per HZ case prevented 
(€/HZ) and € per QALY gained (€/QALY), 
were calculated. All analyses were calcu­
lated from a societal perspective, i. e., in­
cluding costs for absenteeism from work. 
In addition to a base­case analysis (vacci­
nation at age 60 years, assumed immuni­
zation costs of € 182 per person vaccinat­
ed, 35.3% vaccination coverage, and 3% 
annual discount rate of costs and bene­
fits), descriptive univariate and probabil­
istic sensitivity analyses were conducted, 
to identify the impact of uncertain input 
factors. The model was developed using 
the programming language R (The R Pro­
ject for Statistical Computing, Vienna, 
Austria).
12.2 Input data
Data on epidemiology and on direct and 
indirect treatment costs of HZ and PHN 
were taken from invoicing data by the as­
sociations of statutory health insurance 
(SHI) physicians (KV) and from SHI funds 
in Germany ([5, 44], Damm et al. (not yet 
published)). The costs for a complete vac­
cination series (two vaccine doses plus ad­
ministration) were assumed to be € 182 
(https://www.rki.de/zoster­impfung). The 
theoretical price per dose (no information 
was available from the manufacturer at the 
time of modeling) was € 84 and adminis­
tration costs were € 7. The data on vaccine 
effectiveness and vaccine­induced period 
of protection have been described above. 
Quality­of­life data for calculating QALYs 
were taken from patients with HZ or PHN 
disease in Canada [45].
12.3 Results
Of one million 50­year­olds without HZ 
vaccination in the model cohort, 260,000 
will develop HZ in the remaining course of 
their lives (cf. 263,228/1,000,000 = 26.3%), 
and 15,000 will develop PHN (cf. 
15,325/1,000,000 = 1.5%). In the base­case 
scenario, 21,924 HZ cases (NNV = 15), 
i. e., 8.33% of HZ cases that would occur 
without vaccination, could be prevent­
ed with the HZ/su inactivated vaccine 
(. Fig.  10). A higher vaccination rate 
of e. g. 60% (80%) could prevent 24,843 
(37,264) HZ cases. The potential reduc­
tion in HZ cases varies according to age at 
vaccination. It is highest with vaccination 
at age 60 years (8.3%) and lowest with vac­
cination at age 80 years (3.9%) (. Fig. 10). 
The lowest NNV was achieved with vacci­
nation at the ages of 60 and 65 years, with 
15 for each. According to the model, the 
most PHN cases can be prevented with 
vaccination at the age of 70 years (9.9%), 
followed by 9.8% for vaccination at age 
65 years and 9% for vaccination at age 60 
years (. Fig. 11). The NNV to prevent one 
PHN case also varies according to age at 
vaccination, and ranges from 421 for vac­
cination at age 50 years to 197 for vaccina­
tion at age 70 years (. Fig. 11).
Vaccination with the HZ/su inactivat­
ed vaccine leads to ICERs of € 1774/HZ 
and € 23,934/QALY in the base­case sce­
nario. Vaccination at age 65 years appears 
to be the most cost­effective, but the dif­
ference between vaccination at age 60 
years is small (. Fig. 12).
In other sensitivity analyses, it was 
shown that especially the vaccine­in­
duced period of protection, price of the 
vaccine, and recurrence rate of HZ have 
the greatest impact on base­case results. 
If theoretical lifelong vaccine protection is 
Fig. 10 9 Number of HZ 
cases with and without 
vaccination with the HZ/
su inactivated vaccine 
and number needed to 
vaccinate (NNV) according 
to age at vaccination (vac-
cination coverage 35.5%, 
cohort size 1,000,000, 
undiscounted)
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assumed, the ICER falls to € 8523/QALY 
for vaccination at age 60 years. Assuming 
a period of protection of only 5 years leads 
to an ICER of € 86,678/QALY, if the im­
munization costs fall from € 182 to € 100, 
the resulting ICER is € 11,437/QALY; if 
these costs rise to € 282, the ICER is then 
€ 39,173/QALY (. Fig. 12).
12.4 Conclusions from modelling
In a cohort of one million 50­year­olds 
that were followed up until the end of 
their life, modeling the epidemiological 
effects of HZ vaccination revealed that 
vaccination at age 60 would prevent most 
HZ cases and vaccination at age 70 would 
prevent most PHN cases. The health eco­
nomic model showed the best cost­effec­
tiveness with vaccination at age 65 years, 
which was only slightly better than vacci­
nation at 60 years of age. NNV was low­
est for vaccination at ages 60 and 65 years, 
with the same values. As results on VE 
against PHN are based on very few cases 
(see . Table 2) and prevention of HZ is 
the precondition for preventing PHN, and 
because vaccination at age 60 years would 
prevent most HZ cases according to the 
model, 60 years of age seem to be the best 
age for vaccination, from an epidemiolog­
ic point of view.
13 Evaluation of the vaccination 
recommendation
13.1 Epidemiology monitoring
From invoicing data of the associations 
of SHI physicians, diagnostic data are 
available for monitoring the epidemiolo­
gy of HZ and PHN in individuals insured 
under SHI [5]. Information on HZ and 
PHN epidemiology before the introduc­
tion of vaccination is available from the 
same data source, such that a potential ef­
fect of vaccination at population level can 
be assessed very well using the same data 
source. Furthermore, HZ is a notifiable 
disease in the federal states of Branden­
burg and Saxony, according to state reg­
ulations; thus, further population­based 
epidemiological data are available for the 
comparison of age specific HZ­incidenc­
es in periods pre­ and post­introduction 
of vaccination.
13.2 Monitoring of adverse drug 
reactions
Surveillance systems have been estab­
lished in Germany at the Paul Ehrlich 
Institute for Vaccines and Biomedicines 
(PEI) for the spontaneous recording of 
suspected cases of possible adverse events 
after vaccination. According to the Ger­
man Medicines Act (Arzneimittelgesetz, 
AMG), possible side effects of vaccines 
must be reported by the marketing au­
thorization holder and/or pharmaceuti­
cal company. Doctors are also required 
to report suspected cases of vaccine com­
plications in accordance with the Pro­
tection Against Infection Act (IfSG) [46, 
47]. Examples of how these data can be 
used include conducting observed ver­
sus expected analyses and examination 
of whether certain events occur more fre­
quently among those recently vaccinated 
than would be expected, compared with 
background incidence for the age group; 
Fig. 11 9 Number of PHN 
cases with and without 
vaccination with the HZ/
su inactivated vaccine and 
NNV according to age at 
vaccination (vaccination 
coverage 35.5%, cohort 
size 1,000,000, undis-
counted)
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in addition, the data can be used in quan­
titative methods, such as the proportional 
reporting ratio (PRR).
If illnesses occur in temporal correla­
tion to vaccinations, it is important to dis­
tinguish between a causal link and coinci­
dental events. For that reason, researchers 
at the Robert Koch Institute (RKI) and 
PEI are conducting a joint project to de­
termine estimators of the background 
incidence in selected immune­mediat­
ed diseases, orthostatic hypotension, my­
ocardial infarction, stroke, and sudden 
death in adults age ≥ 50 years in Germa­
ny. Based on these estimators, the expect­
ed number of newly occurring diseases 
in a certain time interval, independent 
of vaccination with the HZ/su inactivat­
ed vaccine, can be calculated. This can be 
used in a comparison with the observed 
number of these diseases after introduc­
tion of the HZ/su inactivated vaccine, to 
generate warnings should the comparison 
point to an elevated number of rare ad­
verse side effects.
13.3. Vaccination coverage 
monitoring
The aforementioned invoicing data from 
the associations of SHI physicians on vac­
cinations and relevant diagnoses (HZ, 
PHN) can be used and analyzed [48]. This 
facilitates the determination of nationwide 
vaccination coverage among people in­
sured under SHI (around 85% of the pop­
ulation). These data are available with a 
6­month delay. In addition, incidences of 
the target diseases can be determined ac­
cording to age and risk group by the same 
data source, such that the implementation 
of HZ vaccination recommendations and 
their impact can be evaluated using this 
system.
13.4 Summary evaluation of the 
vaccination recommendation
For the ongoing evaluation of HZ vacci­
nation recommendations, various surveil­
lance and monitoring systems have been 
implemented that permit the continuous 
recording of data on HZ and PHN epide­
miology, the occurrence of adverse effects 
of vaccination, and HZ vaccination cov­
erage. Data collection via these systems 
was in place prior to the introduction of 
HZ vaccination. Thus, reliable evaluation 
of the vaccination recommendation is 
possible by comparing data between the 
pre­ and post­vaccination phases. Using 
the available data, it is possible to assess 
vaccine effectiveness after vaccination by 
age and risk groups as well as over time. 
In addition, international publications 
are continuously reviewed, which report 
on vaccine effectiveness, duration of vac­
cine­induced protection, and vaccine safe­
ty; the results will be analyzed and com­
pared with the data from Germany. This 
will contribute to answering any remain­
ing questions, such as how long the vac­
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